 A randomized, sham-controlled, double-blinded and parallel group trial 12 therapeutic sessions with optimal protocol defined in phase 1 and sham tDCS will be conducted to evaluated electrical cortical activity and pain control, number of migraine attacks and quality of life of migraine patients. Electrical cortical activity will be assessed through: i motor evoked potential MEP; ii motor threshold MT; iii short interval intracortical inhibition SICI; iv intracortical facilitation ICF; v phosphene threshold PT and vi visual evoked-potential VEP-habituation. Clinical outcomes will be evaluated through: i headache diary; ii visual analog scale VAS; iii Migrainde disability assessment MIDAS; iv Headache Impact Test HIT-6 and v World Health Organization quality of life assessment instrument WHOQOL BREF. 